Cardiac allograft vasculopathy coronary angiography: Difference between revisions

Jump to navigation Jump to search
Line 15: Line 15:


===Limitations===
===Limitations===
# Lower sensitivity compared with histopathological studies, [[intravascular ultrasound]] (IVUS) and [[optical coherence tomography]] (OCT), especially in detecting early-stage CAV
# Lower [[sensitivity]] compared with histopathological studies, [[intravascular ultrasound]] ([[IVUS]]) and [[optical coherence tomography]] ([[OCT]]), especially in detecting early-stage CAV
# Risk of [[contrast nephropathy]] in [[heart transplant]] subjects in whom [[chronic renal failure]] is a usual comorbidity
# Risk of [[contrast-induced nephropathy|contrast nephropathy]] in [[heart transplant]] subjects in whom [[chronic renal failure]] is a usual comorbidity


==References==
==References==

Revision as of 15:54, 4 August 2014

Cardiac allograft vasculopathy Microchapters

Home

Patient Information

Overview

Historical Perspective

Pathophysiology

Differentiating Cardiac allograft vasculopathy from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

Chest X Ray

Coronary Angiography

Intravascular Ultrasound

Optical Coherence Tomography

CT

MRI

Echocardiography

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Cardiac allograft vasculopathy coronary angiography On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Cardiac allograft vasculopathy coronary angiography

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Cardiac allograft vasculopathy coronary angiography

CDC on Cardiac allograft vasculopathy coronary angiography

Cardiac allograft vasculopathy coronary angiography in the news

Blogs on Cardiac allograft vasculopathy coronary angiography

Directions to Hospitals Treating Cardiac allograft vasculopathy

Risk calculators and risk factors for Cardiac allograft vasculopathy coronary angiography

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Aarti Narayan, M.B.B.S [2]; Raviteja Guddeti, M.B.B.S. [3]

Overview

Early diagnosis of cardiac allograft vasculopathy (CAV) is of utmost importance as it allows alterations to optimal immunosuppression and risk factor modification prolonging graft survival and reducing morbidity and mortality. In most transplant centers coronary angiography is currently used to screen and diagnose transplant associated coronary artery disease.

Coronary Angiography

Previously, the diagnosis of CAV was made pathologically. However, with the advent of calcineurin-based immunosuppression post-cardiac transplant survival improved significantly and angiographic diagnosis became a standard. Currently, the International Society for Heart and Lung Transplantation (ISHLT) recommends annual invasive coronary angiography as the standard imaging technique to screen for CAV.[1] Angiographic evidence of coronary artery disease is very common after heart transplantation. In a multiinstitutional study by Constanzo et al it was demonstrated that by the end of 5 years after transplantation 42% of heart transplant subjects had angiographic evidence of graft coronary artery disease.[2]

Advantages

  1. Wide acceptability
  2. Reduced healthcare cost compared with other novel intracoronary imaging techniques
  3. Ease of performance

Limitations

  1. Lower sensitivity compared with histopathological studies, intravascular ultrasound (IVUS) and optical coherence tomography (OCT), especially in detecting early-stage CAV
  2. Risk of contrast nephropathy in heart transplant subjects in whom chronic renal failure is a usual comorbidity

References

  1. Costanzo MR, Dipchand A, Starling R, Anderson A, Chan M, Desai S; et al. (2010). "The International Society of Heart and Lung Transplantation Guidelines for the care of heart transplant recipients". J Heart Lung Transplant. 29 (8): 914–56. doi:10.1016/j.healun.2010.05.034. PMID 20643330.
  2. Costanzo MR, Naftel DC, Pritzker MR, Heilman JK, Boehmer JP, Brozena SC; et al. (1998). "Heart transplant coronary artery disease detected by coronary angiography: a multiinstitutional study of preoperative donor and recipient risk factors. Cardiac Transplant Research Database". J Heart Lung Transplant. 17 (8): 744–53. PMID 9730422.

Template:WH Template:WS